PENPenumbra, Inc.

$13B

Q1 2022 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

$204M+20.5% YoY

Gross Profit

$127M62.5% margin

Operating Income

-$4M-2.0% margin

Net Income

$79,0000.0% margin

EPS (Diluted)

$0.00

QoQ Revenue Growth

-0.1%

Cash Flow

Operating Cash Flow

-$5M

Free Cash Flow

-$9M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$342M

Stockholders' Equity

$959M

Cash & Equivalents

$68M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$204M	$169M	+20.5%
Gross Profit	$127M	$111M	+14.4%
Operating Income	-$4M	$13M	-130.1%
Net Income	$79,000	$12M	-99.3%

Revenue Segments

Peripheral Vascular

$123M60%

Neuro

$81M40%

Geographic Segments

UNITED STATES

$144M71%

Other Non-US

$60M29%

PEN Q1 2022 Earnings — Penumbra, Inc. Revenue & Financial Results | Market Cap Arena